CapyFin

Loading...

CapyFin Real-time Earnings Reports.

X LinkedIn

Products

Earnings

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

Cue Biopharma

🇺🇸 NASDAQ:CUE

View Company

Overview Earnings Dividends

May 09, 2024

•

Mar 31, 2024

Cue Biopharma Q1 2024 Earnings Report

Reported collaboration revenue increase and advanced clinical trials.

Key Takeaways

Cue Biopharma reported a collaboration revenue increase due to the Ono Pharmaceutical agreement and advancements in clinical trials for CUE-101 and CUE-102. The company's cash and cash equivalents are expected to fund operations into the first quarter of 2025.

CUE-101 and CUE-102 abstracts accepted for presentations at ASCO 2024.

Advanced preclinical CUE-401 program in collaboration with Ono Pharmaceutical.

Expanded pipeline with CUE-500 series for autoimmune and inflammatory diseases.

Immuno-STAT™ platform posters accepted for presentation at PEGS Boston Summit 2024.

Total Revenue

$1.72M

Previous year: $187K

+818.2%

EPS

-$0.25

Previous year: -$0.29

-13.8%

Weighted Average Common Shares Outstanding Basic and Diluted

49.47M

Gross Profit

$868K

Previous year: $187K

+364.2%

Cash and Equivalents

$41M

Previous year: $56.3M

-27.2%

Free Cash Flow

-$9.84M

Previous year: -$10.8M

-9.2%

Total Assets

$54M

Previous year: $81.7M

-33.9%

Cue Biopharma

Cue Biopharma Revenue by Segment

Revenue by Segment

Collaboration Revenue

CapyFin.com

Forward Guidance

The company expects its current cash and cash equivalents to fund operations into the first quarter of 2025.

Company Overview

Full financial data and analysis

View Cue Biopharma